Let’s reduce gene therapy manufacturing costs by optimizing cell lines, improving transfectants, and optimizing downstream purification.

Why are compounds still failing at the final hurdle?

Only when greater transparency is established in supply chains can the industry begin to iron out problems with drug shortages.

If we learn more about drug–nutrient interactions, we may be on the path towards better medicines.

The pharmaceutical industry must be encouraged to look beyond patients in advanced economies.

How will the adoption of novel approaches to the development of excipients help overcome the challenges of poorly soluble APIs?

"Moving beyond Cas9 may be the secret to reducing CRISPR’s off-target effects," says Garrett Rettig.

Now that Gene therapy's promise has been shown, the industry must focus on improving the manufacturing process and bring down costs.

Miguel Forte argues it’s time to fine tune the way we target solid tumors...